计算溶液所需的质量、体积或浓度。
Dihydrocapsiate, as a compound of capsinoid family, is an orally active TRPV1 agonist. Dihydrocapsiate can be used for the research of metabolism disease
In Vitro
Dihydrocapsiate (10, 25 and 50 μM; 48 hours; human preadipocytes) does not affect cell viability. Dihydrocapsiate (10 and 20 μM; 8 days; mature adipocytes) markedly decreases the expression levels of other adipogenic markers (such as SREBP1, FABP4, PLIN1, ADIPOQ and LEPTIN) and inflammatory markers (MCP1 and TNFα), whereas it enhances the expression levels of PGC1α (master regulator of mitochondrial biogenesis) and TBX1 (marker of “brite” cell). Dihydrocapsiate (25~200 μM; RAW 264.7 cells) prevents NO release and intracellular ROS generation. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: Human preadipocytes Concentration: 10, 25 and 50 μM Incubation Time: 48 hours Result: Did not affect cell viability. RT-PCRCell Line: Mature adipocytes Concentration: 10 and 20 μM Incubation Time: 8 days Result: Markedly decreased the expression levels of other adipogenic markers (such as SREBP1, FABP4, PLIN1, ADIPOQ and LEPTIN) and inflammatory markers (MCP1 and TNFα), whereas it enhanced the expression levels of PGC1α (master regulator of mitochondrial biogenesis) and TBX1 (marker of “brite” cell).
In Vivo
Dihydrocapsiate (2 and 10 mg/kg; p.o.) improves morphometric parameters and insulin levels, prevents high fat diet (HFD)-induced adipocyte size and enhances energy expenditure-related genes in WAT, alleviates HFD-induced hepatic steatosis, prevents HFD-induced fat deposition and enhances mitochondrial biogenesis genes in BAT and improves intestinal morphology and modulates SCFA availability. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: HFD-fed mice Dosage: 2 and 10 mg/kg Administration: P.o. Result: Improved morphometric parameters and insulin levels, prevented HFD-induced adipocyte size and enhanced energy expenditure-related genes in WAT, alleviated HFD-induced hepatic steatosis, prevented HFD-induced fat deposition and enhanced mitochondrial biogenesis genes in BAT and improved intestinal morphology and modulates SCFA availability.
Form:Oil
IC50& Target:TRPV1
分类树(Taxonomy Tree)
| 界(kingdom) | 有机化合物 |
|---|---|
| 超类(Superclass) | 苯类化合物 |
| 类(Class) | 酚类 |
| 亚类(Subclass) | 甲氧基苯酚 |
| 中间层级节点(Intermediate Tree Nodes) | 暂无 |
| 直接上位类(Direct Parent) | 甲氧基苯酚 |
| 其他上位类(Alternative Parents) | 苄氧羰基 苯氧基化合物 甲氧基苯 茴香醚 脂肪酸酯 烷基芳基醚 1-羟基-2-未取代苯类化合物 羧酸酯 一元羧酸及其衍生物 有机氧化物 碳氢化合物衍生物 羰基化合物 |
| 分子骨架(Molecular Framework) | 芳香族同单环化合物 |
| 取代基(Substituents) | 1-羟基-2-未取代苯环化合物 - 芳基醚 - 茴香醚 - 芳香族同单环化合物 - 苄氧羰基 - 羰基 - 羧酸衍生物 - 羧酸酰胺 - 乙醚 - 脂肪酸酯 - 脂肪酰基 - 烃衍生物 - 甲氧基苯 - 甲氧基苯酚 - 单羧酸或其衍生物 - 单环苯基基团 - 有机氧化物 - 有机氧化合物 - 有机氧化合物 - 苯酚醚 - 苯氧基化合物 |
| 描述(Description) | 该化合物属于甲氧基酚类有机化合物。这类化合物在酚基团的苯环上连接有甲氧基。 |
| 外部描述符(External Descriptors) | 暂无 |
H413: 可能对水生生物造成长期持续有害影响